ChemDiv, a California-based global provider of integrated drug discovery solutions, announced on Friday that it is continuing to provide chemistry, computational and clinical pharmacology support to Clywedog Therapeutics.
The company is taking this step as it enters into a definitive merger agreement with Barinthus Therapeutics (NASDAQ: BRNS). The merged company will operate under the name Clywedog Therapeutics Inc and is expected to be listed on Nasdaq under the ticker CLYD upon closing.
The merged portfolio will concentrate on advancing clinical-stage candidates in Type 1 diabetes (T1D), Type 2 diabetes (T2D), and celiac disease.
ChemDiv's ongoing partnerships includes accelerated CMC research, AI-enabled pharmacology, computational modelling and translational biology, extending the successful transition of Clywedog's programs to the clinic in 2023-2024.
DATROWAY receives US priority review for first-line metastatic triple negative breast cancer
Valneva and Instituto Butantan launch pilot chikungunya vaccination campaign in Brazil
Natera submits Signatera CDx PMA to FDA for bladder cancer use
Astrazeneca Imfinzi perioperative regimen gains positive EU CHMP opinion in early gastric cancer
I Peace generates human iPS cells from NKT cells and offers them for research use
Frontage expands early phase clinical research capabilities across US and China
AstraZeneca agrees obesity and type 2 diabetes collaboration with CSPC
Formation Bio acquires worldwide rights to FHND5032 from CTFH
Summit Therapeutics' BLA for ivonescimab in EGFR-mutated NSCLC accepted by FDA
Almirall receives China approval for Seysara to treat moderate-to-severe acne